Fig. 1

actr10 mutants have swollen axon terminals.

(A) Wild-type larva (pigment free) at 4 dpf carrying the neurod:egfp BAC transgene. By 4 dpf, pLL axons are fully extended and functional synapses have formed with hair cells of primary neuromasts. (B) actr10 mutant axons fully extend but terminals display large swellings. Posterior lateral line ganglion (pLLg) and innervation of the third neuromast (NM3) are indicated. Insets in (A) and (B) show magnified NM3 axon terminals. Arrows in inset point to swellings. Asterisks label areas of the pLL nerve obscured by pigment in the mutant. (C) The mutant axon terminal swelling phenotype can be suppressed by exogenous expression of mRFP-Actr10 in a dose-dependent manner. Proportion of mutants with axon terminal swellings is depicted. (D–F) Injection of TALENS targeting exon 1 of the actr10 genomic locus phenocopies the actr10 mutant axon terminal swelling phenotype in F0 injected larvae (arrows). Axons are labeled by the neurod:egfp BAC transgene (white). Scale bars in A,B = 100 µm.